AVR
data caveat$768M1mo
Anteris Technologies Global Corp
Medical Devices · Cardiac
Structural heart company developing DurAVR, a biomimetic transcatheter aortic valve using proprietary ADAPT tissue technology, currently enrolling the global PARADIGM pivotal trial backed by a strategic partnership with Medtronic.
Data HealthTrials3 of 3 active · stale enrollment
Cash data from Sept 2025 4C(6mo old)Figures from ASX filings · not financial advice
[ VITALS ]
Cash on Hand
$14.1M
Sept 2025 4C
Runway
1moCRITICAL
Based on Sept 2025 4C
Market Cap
$768M
Burn Rate
$30.7M/qtr
Sept 2025 4C
Shares Outstanding
97M
Pipeline Assets
1
3M Price
AVR.ASX$7.900-11.3% 3M
Low $7.300High $9.750
Pipeline Assets (1)
DurAVR THVAortic stenosis (TAVR / valve-in-valve)
Phase 3Discovery
Preclinical
Ph 1
Ph 1/2
Ph 2
Ph 2/3
Ph 3
NDA
Approved
DurAVR THV
Aortic stenosis (TAVR / valve-in-valve)
Capital Raises & Buybacks
show_chart
No capital raise or buyback data
Director Options & Rights
Director
Outstanding
Ex. Price
Expiry
No option data entered yet
Short Interest
ASIC ↗as of 2026-03-27 · 4-day lag
Short position
0.02%
Shares short
0.0M
Aggregated short position data published by ASIC under the Corporations Act. T+4 reporting lag applies. Short interest ≥5% is noteworthy; ≥10% is elevated. Source: ASIC Short Selling Data
Competitive Landscape
3 competitor trialsPhase 2+ · Non-ASX
Aortic Stenosis (Tavr / Valve-In-Valve)3 active trials
3 Ph4
Competitor trials from ClinicalTrials.gov (Phase 2+ historical, Phase 3+ refreshed weekly, active/recruiting, non-ASX sponsors). Approved drugs from OpenFDA (NDA/BLA only). Updated weekly via fetch_competitors.py.
expand_moreClinical Publications
Peer-reviewed papers & conference abstracts via PubMed
2 papers
Clinical Publications
Peer-reviewed papers & conference abstracts via PubMed
EuroIntervention2026-02· DurAVR THV
EuroIntervention2025-09· DurAVR THV
Catalysts (7)
Medtronic co-commercialization agreement details
UpcomingExpectedarrow_upwardHigh30 Sept 2026
TCT 2026 DurAVR clinical data presentation
UpcomingConfirmedremoveMed31 Oct 2026
PARADIGM interim 6-month safety data
UpcomingExpectedremoveMed31 Dec 2026
PARADIGM trial enrollment milestones
UpcomingConfirmedMed
Delivery Consistency Index
Historical delivery and spending consistency — data is limited for recently added companies.
Track record will build as data accumulates — we need completed catalysts with original guidance dates, or at least two quarterly 4Cs, before scoring kicks in.
Clinical Trials(6)
3 activeClinicalTrials.gov ↗
NARecruitingEnrollment stale · 183d
TAVR with DurAVR® THVTAVR with SAPIEN THV series or the Evolut THV series
A Clinical Trial Assessing the Safety and Effectiveness of the DurAVR® THV System
Severe Aortic Stenosis · Valve-in-valve Procedures
RandomizedSingle Blind18 Years+
Primary endpoint Composite of all-cause mortality, all stroke and cardiovascular hospitalization
NANot Yet RecruitingEnrollment stale · 568d
DurAVR™ THV System
DurAVR™ THV EU-EFS
Symptomatic Aortic Stenosis · Severe Aortic Valve Stenosis · Aortic Valve Calcification +2 more
18 Years+
Primary endpoint All-cause mortality or disabling stroke
NAActive Not RecruitingEnrollment stale · 989d
DurAVRTM THV System
Use of DurAVR™ THV System in Subjects With Severe Aortic Stenosis: Early Feasibility Study
Aortic Stenosis · Symptomatic Aortic Stenosis · Severe Aortic Valve Stenosis +1 more
65 Years+
Primary endpoint All-cause mortality or disabling stroke